Angiotensin Converting Enzyme Inhibitors as First Line of Therapy in Managing Essential Hypertension In Patients without Compelling Indications.
Date of Award
Master of Science (MS)
Hypertension (HTN) is one of the most common chronic diseases seen in ambulatory care. It is a major risk factor for the development of cardiovascular diseases including coronary artery disease (CAD), stroke, and heart failure. According to the recent statistical facts on high blood pressure, 67 million American adults have high blood pressure. High blood pressure costs the nation$ 47.5 billion annually in direct medical expenses and$ 3.5 billion each year in lost productivity. About half (47%) of people with the disease have their condition under control (Centers for Disease and Prevention).
The management of HTN is of particular importance for healthcare providers such as nurse practitioners, due to its prevalence and its modifiable risk factor for cardiovascular conditions. The management of HTN has shifted from a sole focus on blood pressure-lowering to that of prevention of cardiovascular and renal disease. Angiotensin-converting enzyme (ACE) inhibitors play a crucial role in treatment of HTN. In addition, ACE inhibitors are beneficial in the prevention of some comorbidities such as nephropathy, new onset diabetes and progression of pre-hypertension to HTN
A comprehensive literature review will be conducted using a wide range of electronic and evidenced-based databases to identify study samples that predominantly focus on ACE inhibitors as first line of therapy in controlling high blood pressure in patients without compelling comorbidities
Sang, Beatrice C., "Angiotensin Converting Enzyme Inhibitors as First Line of Therapy in Managing Essential Hypertension In Patients without Compelling Indications." (2014). Theses and Dissertations. 4760.